同和药业(300636)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300636 同和药业

已收盘 07-22 15:00:00

{"stockData":{"symbol":"300636","market":"SZ","secType":"STK","nameCN":"同和药业","latestPrice":8.98,"timestamp":1721631801000,"preClose":8.77,"halted":0,"volume":3282292,"delay":0,"floatShares":364000000,"shares":422000000,"eps":0.2763,"marketStatus":"已收盘","marketStatusCode":5,"change":0.21,"latestTime":"07-22 15:00:00","open":8.81,"high":9.02,"low":8.73,"amount":29258100,"amplitude":0.0331,"askPrice":8.99,"askSize":61,"bidPrice":8.98,"bidSize":13,"shortable":0,"etf":0,"ttmEps":0.2763,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"adjPreClose":8.77,"symbolType":"stock","openAndCloseTimeList":[[1721611800000,1721619000000],[1721624400000,1721631600000]],"highLimit":9.65,"lowLimit":7.89,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":421527350,"pbRate":1.63,"roa":"--","roe":"1.94%","epsLYR":0.2786,"committee":-0.206757,"marketValue":3785000000,"floatMarketCap":3273000000,"peRate":32.500903,"changeRate":0.0239,"turnoverRate":0.009,"status":0},"requestUrl":"/m/hq/s/300636/wiki","defaultTab":"wiki","newsList":[{"id":"2453759238","title":"同和药业：公司二厂区一期工程共四个车间，均为多功能车间，已结项投入生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2453759238","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453759238?lang=zh_cn&edition=full","pubTime":"2024-07-22 17:03","pubTimestamp":1721639010,"startTime":"0","endTime":"0","summary":"证券之星消息，同和药业(300636)07月22日在投资者关系平台上答复投资者关心的问题。投资者：请问二厂区的工程完工验收了吗？什么时候正式投产？一期的正式生产了吗？二厂区一共有几个车间？多功能车间和专门车间分别有几个？同和药业董秘：感谢您对公司的关注！公司二厂区一期工程共四个车间，均为多功能车间，已结项投入生产。二期工程共七个车间，正在建设过程中。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072200022893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2453755035","title":"同和药业最新公告：公司原料药通过CDE审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2453755035","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453755035?lang=zh_cn&edition=full","pubTime":"2024-07-22 16:31","pubTimestamp":1721637073,"startTime":"0","endTime":"0","summary":"同和药业公告，公司近日从国家药品监督管理局药品审评中心（CDE）“原辅包登记信息公示”平台查询获悉，公司提交的“阿戈美拉汀”原料药通过了CDE审批。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072200020474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2453693753","title":"同和药业(300636.SZ)：阿戈美拉汀原料药通过CDE审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2453693753","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453693753?lang=zh_cn&edition=full","pubTime":"2024-07-22 16:09","pubTimestamp":1721635757,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)发布公告，公司近日从国家药品监督管理局药品审评中心(CDE)“原辅包登记信息公示”平台查询获悉，公司提交的“阿戈美拉汀”原料药通过了CDE审批。阿戈美拉汀适用于治疗成人抑郁症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK4017","CDE","300636"],"gpt_icon":0},{"id":"2452483034","title":"同和药业（300636）7月19日主力资金净买入83.69万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452483034","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452483034?lang=zh_cn&edition=full","pubTime":"2024-07-19 15:23","pubTimestamp":1721373813,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月19日收盘，同和药业报收于8.77元，下跌1.79%，换手率0.83%，成交量3.02万手，成交额2650.59万元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：同和药业2024年一季报显示，公司主营收入2.06亿元，同比下降6.47%；归母净利润4356.28万元，同比上升31.62%；扣非净利润4048.76万元，同比上升23.31%；负债率33.01%，财务费用-556.79万元，毛利率36.67%。同和药业主营业务：化学原料药和医药中间体的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071900026784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2452512703","title":"平安证券：给予同和药业增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2452512703","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452512703?lang=zh_cn&edition=full","pubTime":"2024-07-18 14:30","pubTimestamp":1721284236,"startTime":"0","endTime":"0","summary":"平安证券股份有限公司叶寅,韩盟盟,臧文清近期对同和药业进行研究并发布了研究报告《传统品种业务稳健，高端市场原料药新品放量有望加速》，本报告对同和药业给出增持评级，当前股价为8.93元。同和药业营业收入稳健，2023年公司营业收入为7.22亿元，同比微增，2024Q1收入2.06亿元，同比略有下滑，主要受到下游客户去库影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071800026055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","161027"],"gpt_icon":0},{"id":"2451969216","title":"同和药业（300636）7月15日主力资金净买入533.03万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451969216","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451969216?lang=zh_cn&edition=full","pubTime":"2024-07-15 15:24","pubTimestamp":1721028255,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月15日收盘，同和药业报收于8.8元，下跌6.28%，换手率2.54%，成交量9.27万手，成交额8221.55万元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：同和药业2024年一季报显示，公司主营收入2.06亿元，同比下降6.47%；归母净利润4356.28万元，同比上升31.62%；扣非净利润4048.76万元，同比上升23.31%；负债率33.01%，财务费用-556.79万元，毛利率36.67%。同和药业主营业务：化学原料药和医药中间体的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071500013216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2449258079","title":"同和药业涨5.16%，太平洋二个月前给出“买入”评级，目标价16.50元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449258079","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449258079?lang=zh_cn&edition=full","pubTime":"2024-07-05 16:18","pubTimestamp":1720167481,"startTime":"0","endTime":"0","summary":"今日同和药业涨5.16%，收盘报9.78元。2024年4月26日，太平洋研究员周豫,乔露阳发布了对同和药业的研报《Q1业绩超市场预期，新产品法规市场即将放量》，该研报对同和药业给出“买入”评级，认为其目标价为16.5元，现价距离目标价尚有68.71%的涨幅空间。研报中预测公司2024/25/26年营收为10.00/15.00/22.50亿元，归母净利润为2.00/3.07/4.72亿元，对应当前PE为21/14/9X，持续给予“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为68.66%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500029643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","300636"],"gpt_icon":0},{"id":"2446452398","title":"同和药业：6月27日接受机构调研，国泰基金、纽富斯投资等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2446452398","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446452398?lang=zh_cn&edition=full","pubTime":"2024-06-28 14:14","pubTimestamp":1719555250,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年6月28日同和药业发布公告称公司于2024年6月27日接受机构调研，国泰基金任一林、纽富斯投资杨雪香、申万宏源余玉君、东证锦信王瀚鋆参与。同和药业2024年一季报显示，公司主营收入2.06亿元，同比下降6.47%；归母净利润4356.28万元，同比上升31.62%；扣非净利润4048.76万元，同比上升23.31%；负债率33.01%，财务费用-556.79万元，毛利率36.67%。该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为14.59。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062800025400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2446359975","title":"同和药业最新公告：公司原料药通过巴西国家卫生监督局现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2446359975","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446359975?lang=zh_cn&edition=full","pubTime":"2024-06-26 16:39","pubTimestamp":1719391186,"startTime":"0","endTime":"0","summary":"同和药业公告，公司于4月8日至13日接受了巴西国家卫生监督局官方的全面GMP现场检查，检查产品范围为：化学原料药：醋氯芬酸、阿哌沙班、塞来昔布、克立硼罗、非布司他、富马酸伏诺拉生、加巴喷丁、米拉贝隆、利伐沙班、替格瑞洛、维格列汀。近日，公司收到巴西ANVISA签发的《药品GMP证书》，现场检查结论为合格，即公司以上原料药均通过了巴西ANVISA的GMP现场检查。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600032761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2446963355","title":"同和药业(300636.SZ)：通过巴西国家卫生监督局GMP现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2446963355","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446963355?lang=zh_cn&edition=full","pubTime":"2024-06-26 16:16","pubTimestamp":1719389765,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业 发布公告，公司于2024年4月8日至13日接受了巴西国家卫生监督局官方的全面GMP现场检查，本次检查产品范围为：化学原料药：醋氯芬酸、阿哌沙班、塞来昔布、克立硼罗、非布司他、富马酸伏诺拉生、加巴喷丁、米拉贝隆、利伐沙班、替格瑞洛、维格列汀。近日，公司收到巴西ANVISA签发的《药品GMP证书》，现场检查结论为合格，即公司以上原料药均通过了巴西ANVISA的GMP现场检查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2445023675","title":"同和药业最新公告：米拉贝隆获得欧洲药典适应性证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2445023675","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445023675?lang=zh_cn&edition=full","pubTime":"2024-06-24 17:20","pubTimestamp":1719220812,"startTime":"0","endTime":"0","summary":"同和药业公告，公司于近日收到欧洲药品质量管理局（EDQM）颁发的米拉贝隆欧洲药典适应性证书（CEP）。米拉贝隆用于治疗膀胱过度活动症。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400025288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2445077025","title":"同和药业(300636.SZ)收到米拉贝隆欧洲药典适应性证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2445077025","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445077025?lang=zh_cn&edition=full","pubTime":"2024-06-24 17:15","pubTimestamp":1719220510,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)公告，公司近日收到欧洲药品质量管理局(EDQM)颁发的米拉贝隆欧洲药典适应性证书(CEP)。米拉贝隆是强力和选择性的β3-肾上腺受体激动剂，可通过激活膀胱逼尿肌上的β3-肾上腺受体而提高膀胱充盈和贮尿能力，主要用于治疗膀胱过度活动症。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2445738770","title":"同和药业涨6.62%，太平洋一个月前给出“买入”评级，目标价16.50元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445738770","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445738770?lang=zh_cn&edition=full","pubTime":"2024-06-21 16:20","pubTimestamp":1718958043,"startTime":"0","endTime":"0","summary":"今日同和药业涨6.62%，收盘报11.11元。2024年4月26日，太平洋研究员周豫,乔露阳发布了对同和药业的研报《Q1业绩超市场预期，新产品法规市场即将放量》，该研报对同和药业给出“买入”评级，认为其目标价为16.5元，现价距离目标价尚有48.51%的涨幅空间。研报中预测公司2024/25/26年营收为10.00/15.00/22.50亿元，归母净利润为2.00/3.07/4.72亿元，对应当前PE为21/14/9X，持续给予“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为68.66%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062100032544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","601099"],"gpt_icon":0},{"id":"2445781013","title":"同和药业（300636）6月21日主力资金净卖出599.34万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445781013","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445781013?lang=zh_cn&edition=full","pubTime":"2024-06-21 15:18","pubTimestamp":1718954307,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月21日收盘，同和药业报收于11.11元，上涨6.62%，换手率2.76%，成交量10.07万手，成交额1.1亿元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：同和药业2024年一季报显示，公司主营收入2.06亿元，同比下降6.47%；归母净利润4356.28万元，同比上升31.62%；扣非净利润4048.76万元，同比上升23.31%；负债率33.01%，财务费用-556.79万元，毛利率36.67%。同和药业主营业务：化学原料药和医药中间体的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062100026267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2443622924","title":"同和药业(300636.SZ)2023年度每10股派0.4元 股权登记日为6月20日","url":"https://stock-news.laohu8.com/highlight/detail?id=2443622924","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443622924?lang=zh_cn&edition=full","pubTime":"2024-06-14 20:49","pubTimestamp":1718369390,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)发布公告，公司将实施2023年年度权益分派，每10股派0.4元现金红利(含税)，股权登记日为6月20日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1135765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2441031762","title":"同和药业最新公告：原料药恩格列净通过CDE审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2441031762","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441031762?lang=zh_cn&edition=full","pubTime":"2024-06-07 16:34","pubTimestamp":1717749263,"startTime":"0","endTime":"0","summary":"同和药业公告，公司原料药“恩格列净”通过国家药品监督管理局药品审评中心审批。该原料药适用于治疗2型糖尿病，已批准在上市制剂中使用。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060700030765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2441035745","title":"同和药业(300636.SZ)：“恩格列净”原料药通过CDE审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2441035745","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441035745?lang=zh_cn&edition=full","pubTime":"2024-06-07 15:54","pubTimestamp":1717746842,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)发布公告，公司近日从国家药品监督管理局药品审评中心(CDE)“原辅包登记信息公示”平台查询获悉，公司提交的“恩格列净”原料药通过了CDE审批。恩格列净适用于治疗2型糖尿病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1132652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300636","CDE","BK0239","BK4017"],"gpt_icon":0},{"id":"2441331090","title":"同和药业（300636）6月7日主力资金净卖出154.38万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2441331090","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441331090?lang=zh_cn&edition=full","pubTime":"2024-06-07 15:34","pubTimestamp":1717745674,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月7日收盘，同和药业报收于9.82元，下跌1.7%，换手率1.03%，成交量3.76万手，成交额3692.62万元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：同和药业2024年一季报显示，公司主营收入2.06亿元，同比下降6.47%；归母净利润4356.28万元，同比上升31.62%；扣非净利润4048.76万元，同比上升23.31%；负债率33.01%，财务费用-556.79万元，毛利率36.67%。同和药业主营业务：化学原料药和医药中间体的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060700024232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2441609245","title":"同和药业（300636）6月5日主力资金净卖出83.47万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2441609245","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441609245?lang=zh_cn&edition=full","pubTime":"2024-06-05 15:25","pubTimestamp":1717572310,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月5日收盘，同和药业报收于10.09元，上涨0.5%，换手率1.21%，成交量4.42万手，成交额4470.71万元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：同和药业2024年一季报显示，公司主营收入2.06亿元，同比下降6.47%；归母净利润4356.28万元，同比上升31.62%；扣非净利润4048.76万元，同比上升23.31%；负债率33.01%，财务费用-556.79万元，毛利率36.67%。同和药业主营业务：化学原料药和医药中间体的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060500025627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2435640208","title":"同和药业（300636）5月16日主力资金净卖出355.54万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435640208","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435640208?lang=zh_cn&edition=full","pubTime":"2024-05-16 15:28","pubTimestamp":1715844493,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月16日收盘，同和药业报收于10.57元，下跌1.86%，换手率1.16%，成交量4.23万手，成交额4510.87万元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：同和药业2024年一季报显示，公司主营收入2.06亿元，同比下降6.47%；归母净利润4356.28万元，同比上升31.62%；扣非净利润4048.76万元，同比上升23.31%；负债率33.01%，财务费用-556.79万元，毛利率36.67%。同和药业主营业务：化学原料药和医药中间体的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051600017549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-03-31","address":"江西省宜春市奉新县江西奉新高新技术产业园区","stockEarnings":[{"period":"1week","weight":0.0205},{"period":"1month","weight":-0.1917},{"period":"3month","weight":-0.1004},{"period":"6month","weight":0.0542},{"period":"1year","weight":-0.2393},{"period":"ytd","weight":-0.1448}],"companyName":"江西同和药业股份有限公司","boardCode":"AI0027","perCapita":"24878股","boardName":"医药制造业","registeredCapital":"42152万元","compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0113},{"period":"3month","weight":-0.0191},{"period":"6month","weight":0.0509},{"period":"1year","weight":-0.0642},{"period":"ytd","weight":-0.0036}],"survey":"　　江西同和药业股份有限公司主营业务为化学原料药和医药中间体的研发、生产和销售，主要产品方向为特色化学原料药及中间体、专利原料药中间体。公司是技术驱动型企业，连续多年研发投入占销售额的比例保持在8%-9%，多次被认定为高新技术企业，先后获批组建了“江西省特色原料药工程技术研究中心”、“国家博士后科研工作站”、“江西省企业技术中心”、“江西省博士后创新实践基地”、“江西省新药研发产教融合创新中心”等技术创新平台，具有强大的研发能力和技术创新能力。","serverTime":1721676886452,"listedPrice":14.47,"stockholders":"14649人(较上一季度增加7.72%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"同和药业(300636)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供同和药业(300636)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"同和药业,300636,同和药业股票,同和药业股票老虎,同和药业股票老虎国际,同和药业行情,同和药业股票行情,同和药业股价,同和药业股市,同和药业股票价格,同和药业股票交易,同和药业股票购买,同和药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"同和药业(300636)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供同和药业(300636)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}